@article{Smrdel_Zwitter_Bostjancic_Zupan_Popovic_Kovac_Glavac_Bokal_Jerebic_2016, title={Long-term survival in glioblastoma: methyl guanine methyl transferase (MGMT) promoter methylation as independent favourable prognostic factor}, volume={50}, url={https://radioloncol.com/index.php/ro/article/view/2455}, abstractNote={<span style="font-family: Times New Roman; font-size: small;"> </span><p style="margin: 0cm 0cm 6pt; line-height: normal;"><strong style="mso-bidi-font-weight: normal;"><em style="mso-bidi-font-style: normal;"><span lang="EN-GB" style="font-family: "Times New Roman","serif"; font-size: 12pt; mso-ansi-language: EN-GB;">Objective</span></em></strong></p><span style="font-family: Times New Roman; font-size: small;"> </span><p style="margin: 0cm 0cm 6pt; line-height: normal;"><em style="mso-bidi-font-style: normal;"><span lang="EN-GB" style="font-family: "Times New Roman","serif"; font-size: 12pt; mso-ansi-language: EN-GB;">In spite of significant improvement after multi-modality treatment, prognosis of most patients with glioblastoma remains poor. Standard clinical prognostic factors (age, gender, extent of surgery and performance status) do not clearly predict long-term survival. The aim of this case-control study was to evaluate immuno-histochemical and genetic characteristics of the tumour as additional prognostic factors in glioblastoma. </span></em></p><span style="font-family: Times New Roman; font-size: small;"> </span><p style="margin: 0cm 0cm 6pt; line-height: normal;"><strong style="mso-bidi-font-weight: normal;"><em style="mso-bidi-font-style: normal;"><span lang="EN-GB" style="font-family: "Times New Roman","serif"; font-size: 12pt; mso-ansi-language: EN-GB;">Patients and Methods</span></em></strong></p><span style="font-family: Times New Roman; font-size: small;"> </span><p style="margin: 0cm 0cm 6pt; line-height: normal;"><em style="mso-bidi-font-style: normal;"><span lang="EN-GB" style="font-family: "Times New Roman","serif"; font-size: 12pt; mso-ansi-language: EN-GB;">Long-term survivor (LTS) group were 40 patients with glioblastoma with survival longer than 30 months. Control group were 40 patients with shorter survival and matched to the LTS group according to the clinical prognostic factors. All patients underwent multimodality treatment with surgery, postoperative conformal radiotherapy and temozolomide during and after radiotherapy. Biopsy samples were tested for the methylation of MGMT promoter (methylation specific polymerase chain reaction), IDH1 (</span></em><em style="mso-bidi-font-style: normal;"><span style="font-family: "Times New Roman","serif"; font-size: 12pt;">immunohistochemistry)</span></em><em style="mso-bidi-font-style: normal;"><span lang="EN-GB" style="font-family: "Times New Roman","serif"; font-size: 12pt; mso-ansi-language: EN-GB;">, IDH2, CDKN2A and CDKN2B (multiplex ligation-dependent probe amplification), and 1p and 19q mutations (</span></em><em style="mso-bidi-font-style: normal;"><span style="font-family: "Times New Roman","serif"; font-size: 12pt;">fluorescent in situ hybridization).</span></em></p><span style="font-family: Times New Roman; font-size: small;"> </span><p style="margin: 0cm 0cm 6pt; line-height: normal;"><strong style="mso-bidi-font-weight: normal;"><em style="mso-bidi-font-style: normal;"><span lang="EN-GB" style="font-family: "Times New Roman","serif"; font-size: 12pt; mso-ansi-language: EN-GB;">Results</span></em></strong></p><span style="font-family: Times New Roman; font-size: small;"> </span><p style="margin: 0cm 0cm 6pt; line-height: normal;"><em style="mso-bidi-font-style: normal;"><span lang="EN-GB" style="font-family: "Times New Roman","serif"; font-size: 12pt; mso-ansi-language: EN-GB;">Methylation of MGMT promoter was found in 95% and in 36% in the LTS and control groups, respectively (p < 0.001). IDH1 R132H mutated patients had a non-significant lower risk of dying from glioblastoma (0.7), in comparison to patients without this mutation. Other mutations were rare, with no significant difference between the two groups.<span style="mso-spacerun: yes;"> </span></span></em></p><span style="font-family: Times New Roman; font-size: small;"> </span>}, number={4}, journal={Radiology and Oncology}, author={Smrdel, Uroš and Zwitter, Matjaz and Bostjancic, Emanuela and Zupan, Andrej and Popovic, Mara and Kovac, Viljem and Glavac, Damjan and Bokal, Drago and Jerebic, Janja}, year={2016}, month={Nov.} }